DOI: https://doi.org/10.36347/sjmcr.2026.v14i04.043

Pages: 768-772

Insulinoma is a rare pancreatic neuroendocrine tumour, usually benign and responsible for organic hypoglycaemia. This retrospective study, conducted at the endocrinology department of Mohammed VI University Hospital between 2017 and 2025, reports 13 cases of insulinoma. The average age at diagnosis was 46 years, with a predominance of females. The clinical manifestations were dominated by sweating (69%) and loss of consciousness (61%), with an average diagnostic delay of 28 months. Laboratory tests confirmed hyperinsulinemic hypoglycaemia, and pancreatic MRI allowed tumour localisation in 90% of cases. The majority of lesions were single, small (median 15 mm) and located in the tail of the pancreas. Surgical enucleation was the most commonly performed procedure (91%), with generally uncomplicated postoperative outcomes. Histological analysis confirmed well-differentiated neuroendocrine tumours, classified as G1 or G2 according to the Ki-67 index. The diagnosis of insulinoma is based on the combination of documented hypoglycaemia and high-performance imaging, particularly MRI. Conservative surgery remains the standard treatment. Genetic testing should be considered if MEN1 is suspected